First-Line Nivolumab Plus Chemo Approved for Bladder Cancer
The FDA approved the PD-1 immune checkpoint inhibitor nivolumab (Opdivo) in combination with cisplatin and gemcitabine for the first-line treatment of adults with unresectable or metastatic urothelial carcinoma, the agency announced Thursday. Approval was based on results from the phase III CheckMate-901 trial, which were presented last year at the European Society for Medical Oncology […]
Nivolumab-AVD Boosts PFS in Untreated Hodgkin Lymphoma
CHICAGO — Adding the immune checkpoint inhibitor nivolumab (Opdivo), rather than brentuximab vedotin (Adcetris), to a standard chemotherapy backbone reduced the risk of disease progression or death in newly diagnosed adults and adolescents with advanced-stage classical Hodgkin lymphoma (cHL), according to the SWOG S1826 trial. Patients in the phase III study received six cycles of […]
Possible Role for Ipilimumab in Metastatic Bladder Cancer, Study Suggests
A tailored immunotherapy regimen using nivolumab (Opdivo) induction and “boosts” with nivolumab and high-dose ipilimumab (Yervoy) as second-line treatment for metastatic urothelial cancer was associated with higher response rates compared with historical controls, the phase II TITAN-TCC trial showed. Among 83 patients in the intention-to-treat (ITT) population, a confirmed investigator-assessed objective response occurred in 33% […]
ICI/TKI Combo Maintains Survival Benefit in Advanced RCC
SAN FRANCISCO — First-line nivolumab (Opdivo) plus cabozantinib (Cabometyx) continued to demonstrate clinically meaningful survival benefits in advanced renal cell carcinoma (RCC). An update of the CheckMate 9ER trial, which compared the immune checkpoint inhibitor/tyrosine kinase inhibitor (TKI) doublet with the TKI sunitinib (Sutent), showed that after 44 months of median follow-up, median progression-free survival […]
PD-1 Inhibitor OK’d as Adjuvant Therapy for Bladder Cancer
The FDA has approved nivolumab (Opdivo) as an adjuvant therapy for patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection, regardless of prior neoadjuvant chemotherapy, nodal involvement, or PD-L1 status, Bristol Myers Squibb announced. Nivolumab becomes the first PD-1 inhibitor in UC with an indication in the adjuvant […]